A Phase I study of WVT078, a BCMA×CD3 bsAb, with a gamma-secretase inhibitor (WHG626) in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 1:38 7 months ago 50 Скачать Далее
Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:20 3 years ago 147 Скачать Далее
Teclistamab, a BCMA × Cd3 Bispecific Antibody, in Pts with RRMM: Updated Phase 1 Results International Myeloma Foundation 9:57 3 years ago 1 122 Скачать Далее
Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 1:14 1 year ago 107 Скачать Далее
Updated phase 1 results of teclistamab, a BCMA × CD3 bispecific antibody, in RRMM International Myeloma Foundation 7:25 3 years ago 395 Скачать Далее
Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM International Myeloma Foundation 7:06 3 years ago 1 069 Скачать Далее
Phase I study of teclistamab, a humanized BCMA x CD3 bispecific antibody, in relapsed/refractory MM International Myeloma Foundation 3:44 4 years ago 693 Скачать Далее
SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:30 3 years ago 128 Скачать Далее
Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 1:29 3 years ago 86 Скачать Далее
Teclistamab: BCMA x CD3 bispecific antibody in RRMM VJHemOnc – Video Journal of Hematology & HemOnc 3:41 4 years ago 796 Скачать Далее
First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMM International Myeloma Foundation 4:28 2 years ago 248 Скачать Далее
Exciting results for BCMA/CD3 bispecific elranatamab (PF-3135) in R/R MM VJHemOnc – Video Journal of Hematology & HemOnc 3:34 4 years ago 679 Скачать Далее
REGN5459, a BCMA×CD3 bispecific antibody, in R/R multiple myeloma VJHemOnc – Video Journal of Hematology & HemOnc 5:28 1 year ago 162 Скачать Далее
Updated data: Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ecancer 7:25 2 years ago 130 Скачать Далее
Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma International Myeloma Foundation 8:12 3 years ago 699 Скачать Далее
Talquetamab: GPRC5D-CD3 bispecific antibody in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 4:15 3 years ago 548 Скачать Далее
Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents International Myeloma Foundation 5:53 2 years ago 293 Скачать Далее
Update on Phase I trial of teclistamab in R/R myeloma VJHemOnc – Video Journal of Hematology & HemOnc 3:45 3 years ago 92 Скачать Далее
REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 1st-in-Human Study in RRMM Pts International Myeloma Foundation 7:26 2 years ago 570 Скачать Далее
